Health and Healthcare
Why Aytu BioScience Stock Remains a Promising Coronavirus Play
Published:
Last Updated:
Aytu BioScience Inc. (NASDAQ: AYTU) stock has been a huge beneficiary of the coronavirus pandemic. In fact, Aytu BioScience stock is up 52% year to date and up over 100% in the past six months alone.
For those late to the party, Aytu BioScience is a specialty pharmaceutical company focused on commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility.
The company only branched out into the COVID-19 testing business back in February. Since then Aytu BioScience has expanded its reach with multiple deals.
Sterling Medical Deal
Back in late April, the company signed an agreement with Sterling Medical Devicese to finalize the development of its Healight platform technology. Basically, this is a novel endotracheal catheter that emits ultraviolet light and is a potential treatment for the coronavirus.
Aytu thinks that the Healight platform technology will affect outcomes for critically ill patients with COVID-19 and other infections. The company, with support from Cedars-Sinai, is working with the U.S. Food and Drug Administration (FDA) to determine an expedited regulatory process for Healight. The goal is to enable near-term use of the technology, initially as a coronavirus intervention for critically ill intubated patients.
24/7 Wall St.Other Developments
Separately, Aytu announced an agreement with the Singapore-based firm Biolidics for the exclusive U.S. distribution rights to Biolidics’s COVID-19 IgG/IgM Rapid Test. As a result, the Denver-based company purchased 500,000 tests immediately and committed to purchasing at least 1.25 million more in the first three months of the agreement.
Aytu received 100,000 test kits on April 1, prior to the agreement with Biolidics. The Denver Police Department bought the first 2,750 of these to screen the city’s first responders. On April 15, Aytu said that it had sold all 100,000 tests and was awaiting delivery of more.
The Average American Is Losing Momentum On Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4%1 today. Checking accounts are even worse.
But there is good news. To win qualified customers, some accounts are paying more than 7x the national average. That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn a $200 bonus and up to 7X the national average with qualifying deposits. Terms apply. Member, FDIC.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.